The ongoing Oxford GPS PROTECT study encompasses over 1,500 patients and aims to provide "the highest level of evidence in ...
For ten months, Dickerson combed through investigation reports until she found the evidence: the only fingerprints on the bag and tape belonged to April’s husband. He confessed and he's now in prison ...
India faces a growing crisis in wound treatment, driven by diabetes and an ageing population. A new policy approach could ...
Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.
Market valued at $1.45B in 2024 grows at 10.4% CAGR driven by biocompatible hemostatic solutions in surgical and trauma ...
MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) ...
The AAR held that Dry Citrate Powder used in haemodialysis is not an instrument or apparatus under Chapter 90. It was classified under HSN 29181590 as an organic chemical, attracting 18% ...
BuzzFeed on MSN
People are sharing the absolutely bonkers things their teachers did, and I'm genuinely concerned about the education system
"My gym teacher picked a kid up by his unusually large ears. Nobody cared because it was the '80s." View Entire Post › ...
MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST)Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 202 ...
Morning Overview on MSN
Fast-aging fish exposes kidney aging and common drug that shields them
The African turquoise killifish ages so quickly that its entire life story can unfold between one human birthday and the next. That compressed timeline is helping scientists watch kidney aging in fast ...
Nature does it again! The natural world has a knack for giving us the blueprints for some useful technologies, and the humble sea urchin is the latest contributor. Scientists have designed a new class ...
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results